关注
Nigel Irwin
Nigel Irwin
Senior Lecturer, Ulster University
在 ulster.ac.uk 的电子邮件经过验证
标题
引用次数
引用次数
年份
Handbook of biologically active peptides
A Kastin
Academic press, 2013
7182013
GIP receptor antagonism reverses obesity, insulin resistance, and associated metabolic disturbances induced in mice by prolonged consumption of high-fat diet
PL McClean, N Irwin, RS Cassidy, JJ Holst, VA Gault, PR Flatt
American Journal of Physiology-Endocrinology and Metabolism 293 (6), E1746-E1755, 2007
2722007
Chemical ablation of gastric inhibitory polypeptide receptor action by daily (Pro3) GIP administration improves glucose tolerance and ameliorates insulin resistance and …
VA Gault, N Irwin, BD Green, JT McCluskey, B Greer, CJ Bailey, P Harriott, ...
Diabetes 54 (8), 2436-2446, 2005
1922005
Inhibition of dipeptidyl peptidase-IV activity by metformin enhances the antidiabetic effects of glucagon-like peptide-1
BD Green, N Irwin, NA Duffy, VA Gault, FPM O'harte, PR Flatt
European journal of pharmacology 547 (1-3), 192-199, 2006
1752006
Direct and indirect effects of obestatin peptides on food intake and the regulation of glucose homeostasis and insulin secretion in mice
BD Green, N Irwin, PR Flatt
Peptides 28 (5), 981-987, 2007
1592007
Evidence for beneficial effects of compromised gastric inhibitory polypeptide action in obesity-related diabetes and possible therapeutic implications
N Irwin, PR Flatt
Diabetologia 52, 1724-1731, 2009
1442009
Chemical gastric inhibitory polypeptide receptor antagonism protects against obesity, insulin resistance, glucose intolerance and associated disturbances in mice fed high-fat …
VA Gault, PL McClean, RS Cassidy, N Irwin, PR Flatt
Diabetologia 50, 1752-1762, 2007
1382007
Therapeutic potential for GIP receptor agonists and antagonists
N Irwin, PR Flatt
Best Practice & Research Clinical Endocrinology & Metabolism 23 (4), 499-512, 2009
1272009
A novel glucagon-like peptide-1 (GLP-1)/glucagon hybrid peptide with triple-acting agonist activity at glucose-dependent insulinotropic polypeptide, GLP-1, and glucagon …
VA Gault, VK Bhat, N Irwin, PR Flatt
Journal of Biological Chemistry 288 (49), 35581-35591, 2013
1132013
Early administration of the glucose-dependent insulinotropic polypeptide receptor antagonist (Pro3)GIP prevents the development of diabetes and related metabolic …
N Irwin, PL McClean, FPM O’harte, VA Gault, P Harriott, PR Flatt
Diabetologia 50, 1532-1540, 2007
1112007
Glucose-dependent insulinotropic polypeptide (GIP) receptor deletion leads to reduced bone strength and quality
A Mieczkowska, N Irwin, PR Flatt, D Chappard, G Mabilleau
Bone 56 (2), 337-342, 2013
1102013
Optimal bone mechanical and material properties require a functional glucagon-like peptide-1 receptor.
G Mabilleau, A Mieczkowska, N Irwin, PR Flatt, D Chappard
Journal of Endocrinology 219, 59-68, 2013
972013
Prolonged GIP receptor activation improves cognitive function, hippocampal synaptic plasticity and glucose homeostasis in high-fat fed mice
DW Porter, N Irwin, PR Flatt, C Hölscher, VA Gault
European journal of pharmacology 650 (2-3), 688-693, 2011
882011
A novel CCK-8/GLP-1 hybrid peptide exhibiting prominent insulinotropic, glucose-lowering, and satiety actions with significant therapeutic potential in high-fat–fed mice
N Irwin, V Pathak, PR Flatt
Diabetes 64 (8), 2996-3009, 2015
842015
Glucose-dependent insulinotropic polypeptide receptor deficiency leads to modifications of trabecular bone volume and quality in mice
C Gaudin-Audrain, N Irwin, S Mansur, PR Flatt, B Thorens, M Baslé, ...
Bone 53 (1), 221-230, 2013
822013
Islet distribution of Peptide YY and its regulatory role in primary mouse islets and immortalised rodent and human beta-cell function and survival
D Khan, S Vasu, RC Moffett, N Irwin, PR Flatt
Molecular and cellular endocrinology 436, 102-113, 2016
772016
Stable incretin mimetics counter rapid deterioration of bone quality in type 1 diabetes mellitus
SA Mansur, A Mieczkowska, B Bouvard, PR Flatt, D Chappard, N Irwin, ...
Journal of cellular physiology 230 (12), 3009-3018, 2015
772015
Comparison of the independent and combined effects of sub-chronic therapy with metformin and a stable GLP-1 receptor agonist on cognitive function, hippocampal synaptic …
R Lennox, DW Porter, PR Flatt, C Holscher, N Irwin, VA Gault
Neuropharmacology 86, 22-30, 2014
772014
Cholecystokinin (CCK) and related adjunct peptide therapies for the treatment of obesity and type 2 diabetes
V Pathak, PR Flatt, N Irwin
Peptides 100, 229-235, 2018
752018
Comparison of sub-chronic metabolic effects of stable forms of naturally occurring GIP (1-30) and GIP (1-42) in high-fat fed mice
VA Gault, DW Porter, N Irwin, PR Flatt
Journal of Endocrinology 208 (3), 265, 2011
722011
系统目前无法执行此操作,请稍后再试。
文章 1–20